Sclerotherapy Market Report 2026

The sclerotherapy market size has grown strongly in recent years. It will grow from $1.21 billion in 2025 to $1.29 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to limited treatment awareness, conventional sclerosing agents, low cosmetic procedure adoption, regulatory limitations, high treatment costs.

The sclerotherapy market size is expected to see strong growth in the next few years. It will grow to $1.65 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to development of safer sclerosants, advanced delivery techniques, growth of aesthetic clinics, medical tourism expansion, insurance coverage improvement. Major trends in the forecast period include minimally invasive procedures, advanced foam sclerosants, combination therapies, outpatient treatment growth, rising medical tourism.

The rising prevalence of varicose veins and spider veins is expected to drive the growth of the sclerotherapy market in the coming years. Varicose veins and spider veins are enlarged, twisted, or damaged veins often visible beneath the skin, commonly caused by poor blood flow in the legs. The increasing prevalence of these conditions is linked to modern work habits, with more people spending long periods sitting or standing. Sclerotherapy addresses varicose and spider veins by enabling targeted injections of a solution that closes off damaged veins, improving both blood flow and appearance. For example, in January 2024, the National Center for Biotechnology Information, a US-based health information organization, reported that in Brazil, 47.6% of the population had varicose veins, with a higher prevalence in non-pregnant women (50.9%) compared to men (37.9%). Thus, the growing prevalence of varicose and spider veins is expected to propel the sclerotherapy market.

The increase in healthcare expenditure is anticipated to support the growth of the sclerotherapy market going forward. Healthcare expenditure encompasses overall spending on medical services, treatments, and health-related resources within a country or system. Rising costs are largely driven by the development and implementation of advanced medical technologies, which improve diagnosis and treatment but require significant investment in equipment, specialized personnel, and research. Higher healthcare expenditure enables greater access to specialized treatments, skilled medical staff, and advanced equipment for sclerotherapy. For instance, in May 2024, the UK’s Office for National Statistics reported that healthcare expenditure reached approximately $421.32 billion (£317 billion) in 2024, representing a 6.5% increase compared to 2023. Therefore, the rise in healthcare expenditure is expected to drive sclerotherapy market growth.

Key companies in the sclerotherapy market are emphasizing strategic partnerships to enhance research capabilities, expand product offerings, and strengthen their market presence through shared expertise and global distribution networks. Advanced minimally invasive treatments for varicose veins include procedures such as sclerotherapy, laser therapy, and radiofrequency ablation, which effectively close or remove damaged veins with minimal pain, faster recovery, and reduced risk of complications. For example, in February 2025, Aakash Healthcare, an India-based specialty hospital, partnered with Medtronic plc, a US-based healthcare company, to launch a specialized vein clinic offering advanced minimally invasive treatments for varicose veins and other vein-related conditions. The clinic also provides personalized treatment plans and post-treatment care, ensuring a comprehensive approach to vein health and overall well-being.

Major companies operating in the sclerotherapy market are Bayer AG, Sanofi S.A., Abbott Laboratories, Novartis AG, Medtronic plc, Boston Scientific Corporation, Olympus Corporation, Smith And Nephew plc, Teleflex Incorporated, Cook Medical, Merz Pharma GmbH And Co KGaA, AngioDynamics Inc, Bioniche Pharma Group Ltd, Omega Pharmaceuticals Pvt Ltd, Endo Flex, Kreussler, Vascular Solutions Inc, BTG International Ltd, Boston Biomedical Inc, Cardinal Health Inc, Terumo Corporation, B Braun Melsungen AG, BD Bard, MedAlliance SA.

North America was the largest region in the sclerotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sclerotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sclerotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have had a notable impact on the sclerotherapy market by increasing the cost of imported sclerosants, specialized needles, syringes, and ultrasound-guided delivery equipment that are widely sourced from global suppliers. These added duties have raised procedural costs for hospitals, ambulatory surgical centers, and specialty clinics, particularly in Asia-Pacific and European regions that depend heavily on cross-border pharmaceutical and device supply chains. As a result, pricing pressure has slowed adoption of advanced foam and ultrasound-guided sclerotherapy techniques in cost-sensitive markets. At the same time, tariffs are encouraging manufacturers to localize production and develop cost-optimized formulations, which is gradually strengthening domestic supply resilience and supporting long-term stability in the sclerotherapy market.

The sclerotherapy market research report is one of a series of new reports that provides sclerotherapy market statistics, including sclerotherapy industry global market size, regional shares, competitors with a sclerotherapy market share, detailed sclerotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the sclerotherapy industry. This sclerotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sclerotherapy is a minimally invasive medical treatment for varicose and spider veins, involving the injection of a concentrated solution (sclerosant) directly into the targeted vessels. The sclerosant irritates the vein’s lining, causing it to collapse, form scar tissue, and eventually be absorbed by the body. Over time, the treated veins diminish in appearance, and blood flow is redirected through healthier vessels.

The primary types of sclerotherapy include liquid sclerotherapy, foam sclerotherapy, and ultrasound-guided sclerotherapy. Liquid sclerotherapy entails injecting a solution directly into affected veins and is commonly used for treating varicose and spider veins. The procedure employs various agents, including detergents, chemical irritants, and osmotic agents. These treatments are applied for conditions such as varicose veins, spider veins, and hemorrhoids, and are utilized by a range of end-users including hospitals, ambulatory surgical centers, specialty clinics, and others.

The sclerotherapy market consists of revenues earned by entities by providing services such as spider vein removal, cosmetic vein treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The sclerotherapy market also includes sales of polidocanol asclera, hypertonic saline, sodium tetradecyl sulfate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.